Note 14 - Segment Information

12 Months Ended

Apr. 30, 2015

Notes

Note 14 - Segment Information

 NOTE 14 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, “Segment Reporting”, for fiscal 2015 and 2014; we operated in three reportable business segments - (1) natural sweetener (stevioside), (2) traditional Chinese medicines and (3) corporate and other. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Financial information with respect to these reportable business segments for the fiscal years 2015 and 2014 is as follows:

	Fiscal Years Ended April 30,
	2015	2014
Revenues:
Chinese medicine – third party	$       2,333,789	$    2,429,468
Chinese medicine – related party	0	0
Total Chinese medicine	2,333,789	2,429,468
Stevioside – third party	9,096,329	6,738,685
Stevioside – related party	6,081,939	3,705,504
Total Stevioside	15,178,268	10,444,189
Total segment and consolidated revenues	$     17,512,057	$ 12,873,657
Interest expense:
Chinese medicine	$                       0	$                    0
Stevioside	(368,775)	120,144
Corporate and other	0	0
Total segment and consolidated interest expense	$         (368,775)	$       120,144
Depreciation and amortization:
Chinese medicine	$           531,343	$       164,122
Stevioside	1,558,391	2,000,460
Corporate and other	325,175	0
Total segment and consolidated depreciation and amortization	$       2,414,909	$    2,164,582
Loss before income taxes:
Chinese medicine	$           393,308	$         52,141
Stevioside	3,913,729	2,961,882
Corporate and other	105,761	51,798
Total consolidated loss before income taxes	$       4,412,798	$    3,065,821

	April 30, 2015	April 30, 2014
Segment tangible assets:
Chinese medicine	$    2,285,114	$        605,918
Stevioside	9,800,456	14,332,440
Corporate and other	0	0
Total consolidated assets	$  12,085,570	$  14,938,358